Trials / Unknown
UnknownNCT04571489
A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer
Gimatecan (ST1481) as Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer: an Open-label, Randomized, Controlled Phase II Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Lee's Pharmaceutical Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase II clinical trial studies the safety and effect of as second-line treatmen in local advanced or metastatic pancreatic cancer. The Gimatecan will be given every four weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gimatecan | Patients will receive gimatecan orally at 0.8mg/m2 on day 1-5 every 4 weeks. |
| DRUG | tegafur, gimeracil and oteracil potassium | Patients will receive tegafur, gimeracil and oteracil potassium orally at 40 or 60mg twice daily on days 1 to 14 every 3 weeks. |
| DRUG | gemcitabine | Patients will receive gemcitabine IV at 1000mg/m2 on days 1、8 every 3 weeks. |
Timeline
- Start date
- 2020-12-01
- Primary completion
- 2021-12-01
- Completion
- 2023-12-01
- First posted
- 2020-10-01
- Last updated
- 2020-10-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04571489. Inclusion in this directory is not an endorsement.